Semaglutide for Weight Loss: What the Evidence Actually Shows

How does semaglutide actually reduce body weight?

Semaglutide belongs to a class called GLP-1 receptor agonists. GLP-1 is a hormone your gut releases after eating, and it plays several roles: it signals to the brain that you have eaten, slows the rate at which your stomach empties, and reduces the urge to keep eating. Semaglutide mimics that hormone and prolongs its effect well beyond a normal meal window. The result, for most people, is a measurable reduction in appetite and calorie intake without the constant conscious effort of traditional dieting.

It is worth understanding what semaglutide is not doing. It is not a stimulant, and it does not block fat absorption. The weight loss comes primarily from eating less, but the biology behind that is more complex than willpower alone. For a deeper look at the mechanism, the detail on how semaglutide causes weight loss is worth reading before you start. The NHS patient-level overview of semaglutide on the NHS website also gives a clear, accessible account of how it works and what side effects to expect.

One practical note: the medicine works best alongside genuine changes to diet and activity. Trials recruited participants who also received lifestyle support, and prescribers at a regulated service will discuss that with you.

Who does the UK licence actually cover?

Under the Wegovy licence, semaglutide is indicated for adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower thresholds apply for some ethnic backgrounds under UK clinical guidance, typically 2.5 kg/m² below the standard figures. The eligibility detail for semaglutide weight loss covers the nuance in full.

BMI alone does not determine approval. A prescriber considers your full medical history, any medicines you already take, and whether weight-related conditions are present, and if you are taking a biologic such as Cosentyx it is worth checking whether Wegovy and Cosentyx can be taken together before you begin. Certain situations rule semaglutide out entirely: pregnancy, breastfeeding, and actively trying to conceive are all contraindications, as is a personal or family history of medullary thyroid carcinoma or a condition called MEN2. Semaglutide is not licensed for under-18s. Anyone with a history of pancreatitis needs to have a careful conversation with their prescriber before starting.

NICE recommended semaglutide for NHS use under technology appraisal TA875, though the NHS criteria are considerably stricter than the private licence and access is channelled through specialist weight management services with multidisciplinary support.

What does starting treatment actually look like?

Treatment begins at 0.25mg weekly, a dose chosen purely to help your body adjust rather than to produce meaningful weight loss straight away. From there, the prescriber typically increases the dose every four weeks: 0.5mg, then 1.0mg, then 1.7mg, and finally 2.4mg as the standard maintenance level. The pace of that schedule depends on how well you tolerate each step. Some people move through it quickly; others need longer at a lower dose.

The pen itself is pre-filled and pre-set at each strength. When a pen arrives from a GPhC-registered pharmacy, it comes in plain, unbranded packaging via a tracked courier service, and the DPD notification gives you a one-hour delivery window so it is not left on a doorstep in warm weather. Pens are stored in the fridge between 2 and 8°C; the Patient Information Leaflet specifies the limited window during which a pen can be kept at room temperature.

For practical guidance on technique and timing, how to use Wegovy for weight loss and the best approach to getting results on Wegovy both address the day-to-day questions that come up most often.

What side effects should you know about before starting?

The most common side effects are gastrointestinal: nausea, loose stools, constipation, indigestion and burping. They are most pronounced in the first week or two after a dose increase and tend to settle as the body adjusts. Eating smaller portions, avoiding rich or fatty meals, and staying well hydrated all help. Fatigue and mild headaches are reported by some people, particularly early in treatment.

More serious but less common effects deserve clear mention. Acute pancreatitis is a known risk with GLP-1 medicines. Severe stomach pain that radiates to the back, with or without vomiting, needs urgent medical attention, not a wait-and-see approach. The MHRA highlighted this in a Drug Safety Update published in January 2026. Gallbladder problems have also been reported, particularly in people losing weight rapidly, which is one reason the graduated dose schedule matters. Anyone experiencing symptoms they are unsure about can report them directly via the Yellow Card scheme.

A full side-effect profile, including what to watch for and when to call for help, is covered on the Wegovy overview page. If you have questions about a specific interaction or situation, the support team can point you to the right clinical resource.